Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic

Movement Disorders

Volumn 33, Issue 5, 2018, Pages 684-696

  Sardi, S Pablo ^a   Cedarbaum, Jesse M ^b   Brundin, Patrik ^c  

^a SANOFI   (France)

^b BIOGEN   (United States)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

clinical trial; GBA LRRK2; glucocerebrosidase; SNCA; synuclein

Indexed keywords

ALPHA SYNUCLEIN; AMBROXOL; ANTIPARKINSON AGENT; BIIB 054; DNL 201; GLUCOSYLCERAMIDASE; LEUCINE RICH REPEAT KINASE 2; MEDI 1341; NILOTINIB; NPT 088; NPT 200 11; PD 01A; PD 03A; RO 7046015; UNCLASSIFIED DRUG; VENGLUSTAT; PROTEIN SERINE THREONINE KINASE;

AUTOPHAGY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; GENETICS; HUMAN; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; ANIMAL; CLINICAL TRIAL (TOPIC); PROCEDURES;

ALPHA-SYNUCLEIN; ANIMALS; CLINICAL TRIALS AS TOPIC; GLUCOSYLCERAMIDASE; HUMANS; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES;

EID: 85046011853     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.27414     Document Type: Review

References (103)

1. Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Primers 2017;3:17013.
2. Lang AE, Espay AJ. Which therapeutic developments are more likely to modify progression in Parkinson's disease? Mov Disord 2018
3. Domingo A, Klein C. Genetics of Parkinson disease. Handb Clin Neurol 2018;147:211-227.
4. Goedert M, Jakes R, Spillantini MG. The synucleinopathies: twenty years on. J Parkinsons Dis 2017;7(suppl 1):S53-S71.
5. Burre J. The synaptic function of alpha-synuclein. J Parkinsons Dis 2015;5(4):699-713.
6. Nalls MA, Pankratz N, Lill CM, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 2014;46(9):989–993. doi: 10.1038/ng.3043
7. Chang D, Nalls MA, Hallgrimsdottir IB, et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. Nat Genet 2017;49(10):1511-1516.
8. Dehay B, Bourdenx M, Gorry P, et al. Targeting alpha-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurol 2015;14(8):855-866.
9. Koprich JB, Kalia LV, Brotchie JM. Animal models of alpha-synucleinopathy for Parkinson disease drug development. Nat Rev Neurosci 2017;18(9):515-529.
10. Volpicelli-Daley LA, Kirik D, Stoyka LE, Standaert DG, Harms AS. How can rAAV-alpha-synuclein and the fibril alpha-synuclein models advance our understanding of Parkinson's disease? J Neurochem 2016;139(suppl 1):131-155.
11. Luk KC, Kehm V, Carroll J, et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012;338(6109):949-953.
12. Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, Lee VM. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med 2012;209(5):975-986.
13. Rey NL, Steiner JA, Maroof N, et al. Widespread transneuronal propagation of alpha-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's disease. J Exp Med 2016;213(9):1759-1778.
14. Rey NL, Wesson DW, Brundin P. The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases. Neurobiol Dis 2018;109(Pt B):226-248.
15. Eberling JL, Dave KD, Frasier MA. Alpha-synuclein imaging: a critical need for Parkinson's disease research. J Parkinsons Dis 2013;3(4):565-567.
16. Mathis CA, Lopresti BJ, Ikonomovic MD, Klunk WE. Small-molecule PET Tracers for Imaging Proteinopathies. Semin Nucl Med 2017;47(5):553-575.
17. Kotzbauer P, Tu Z, Mach R. Current status of the development of PET radiotracers for imaging alpha synuclein aggregates in Lewy bodies and Lewy neurites. J Clin Trans Imaging 2017;5(1):3-14.
18. Mollenhauer B, Batrla R, El-Agnaf O, et al. A user's guide for alpha-synuclein biomarker studies in biological fluids: perianalytical considerations. Mov Disord 2017;32(8):1117-1130.
19. Sevigny J, Chiao P, Bussiere T, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer's disease. Nature 2016;537(7618):50-56.
20. Braak H, Del Tredici K. Neuropathological staging of brain pathology in sporadic Parkinson's disease: separating the wheat from the chaff. J Parkinsons Dis 2017;7(s1):S73-S87.
21. Alzforum Website. Positive trials of spinal muscular atrophy bode well for antisense approach. https://www.alzforum.org/news/research-news/positive-trials-spinal-muscular-atrophy-bode-well-antisense-approach. Accessed on Feb 1, 2018.
22. Wild EJ, Tabrizi SJ. Therapies targeting DNA and RNA in Huntington's disease. Lancet Neurol 2017;16(10):837-847.
23. Pharmaceuticals Licenses IONISIONIS website. Ionis &#x 2010;HTT Rx to partner following successful phase 1/2a study in patients with Huntington's disease. http://ir.ionispharma.com/news-releases/news-release-details/ionis-pharmaceuticals-licenses-ionis-htt-rx-partner-following
24. Zharikov AD, Cannon JR, Tapias V, et al. shRNA targeting alpha-synuclein prevents neurodegeneration in a Parkinson's disease model. J Clin Invest 2015;125(7):2721-2735.
25. Cole T, Paumier K, Zhao H, Weihofen A, Kordasiewicz HB, Swayze EE. Snca targeted antisense oligonucleotides mediate progression of pathological deposition in alpha synuclein rodent transmission models of Parkinson's disease. Neurology 2016;86(16 suppl):P6.239.
26. Gorbatyuk OS, Li S, Nash K, et al. In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration. Mol Ther 2010;18(8):1450-1457.
27. Mittal S, Bjornevik K, Im DS, et al. beta2-Adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson's disease. Science 2017;357(6354):891-898.
28. Gironell A, Kulisevsky J. Diagnosis and management of essential tremor and dystonic tremor. Ther Adv Neurol Disord 2009;2(4):215-222.
29. Bhatt MA, Messer A, Kordower JH. Can intrabodies serve as neuroprotective therapies for Parkinson's disease? Beginning thoughts. J Parkinsons Dis 2013;3(4):581-591.
30. Xilouri M, Brekk OR, Stefanis L. alpha-Synuclein and protein degradation systems: a reciprocal relationship. Mol Neurobiol 2013;47(2):537-551.
31. Poehler AM, Xiang W, Spitzer P, et al. Autophagy modulates SNCA/alpha-synuclein release, thereby generating a hostile microenvironment. Autophagy 2014;10(12):2171-2192.
32. Lopes da Fonseca T, Villar-Pique A, Outeiro TF. The interplay between alpha-synuclein clearance and spreading. Biomolecules 2015;5(2):435-471.
33. Maiese K, Chong ZZ, Shang YC, Wang S. mTOR: on target for novel therapeutic strategies in the nervous system. Trends Mol Med 2013;19(1):51-60.
34. Decressac M, Mattsson B, Weikop P, Lundblad M, Jakobsson J, Bjorklund A. TFEB-mediated autophagy rescues midbrain dopamine neurons from alpha-synuclein toxicity. Proc Natl Acad Sci U S A 2013;110(19):E1817-E1826.
35. Ghosh A, Tyson T, George S, et al. Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson's disease. Sci Trans Med 2016;8(368):368ra174.
36. Brahmachari S, Karuppagounder SS, Ge P, et al. c-Abl and Parkinson's disease: mechanisms and therapeutic potential. J Parkinsons Dis 2017;7(4):589-601.
37. Karuppagounder SS, Brahmachari S, Lee Y, Dawson VL, Dawson TM, Ko HS. The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease. Sci Rep 2014;4:4874.
38. Pagan F, Hebron M, Valadez EH, et al. Nilotinib effects in Parkinson's disease and Dementia with Lewy bodies. J Parkinsons Dis 2016;6(3):503-517.
39. Wyse RK, Brundin P, Sherer TB. Nilotinib—differentiating the Hope from the Hype. J Parkinsons Dis 2016;6(3):519-522.
40. Brundin P, Dave KD, Kordower JH. Therapeutic approaches to target alpha-synuclein pathology. Exp Neurol 2017;298(Pt B):225-235.
41. George S, Brundin P. Solving the conundrum of insoluble protein aggregates. Lancet Neurol 2017;16(4):258-259.
42. Games D, Seubert P, Rockenstein E, et al. Axonopathy in an alpha-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated alpha-synuclein. Am J Pathol 2013;182(3):940-953.
43. Schenk DB, Koller M, Ness DK, et al. First-in-human assessment of PRX002, an anti-alpha-synuclein monoclonal antibody, in healthy volunteers. Mov Disord 2017;32(2):211-218.
44. Jankovic J, Goodman I, Safirstein B, et al. Results from a phase 1b multiple ascending-dose study of PRX002, an anti–alpha-synuclein monoclonal antibody, in patients with Parkinson's disease [abstract]. Mov Disord 2017;32(suppl 2):1418.
45. Weihofen A, Patel H, Huy C, et al. Binding and functional characterization of human-derived anti-alpha-synuclein antibody BIIB054. Neurodegener Dis 2017;17(suppl 1):59.
46. Brys M, Hung S, Fanning L, et al. Randomized, double-blind, placebo-controled, single ascending dose study of anti-alpha synuclein antibody BIIB054 in healthy volunteers. Neurodegener Dis 2017;17(suppl 1).
47. Brys M, Ellenbogen A, Fanning L, et al. Randomized, double-blind, placebo-controlled, single ascending dose study of antialpha-synuclein antibody BIIB054 in patients with Parkinson's disease. Paper presented at: The American Academy of Neurology Annual Meeting Apr 21 - 27, 2018. Los Angeles CA, USA.
48. BioArctic. BioArctic enters into collaboration with AbbVie for Parkinson's disease research. https://www.bioarctic.se/en/bioarctic-enters-into-collaboration-with-abbvie-for-parkinsons-disease-research-2815/. Accessed on Feb 1, 2018.
49. AFFiRiS. AFFiRiS announces top line results of first&#x 2010;in&#x 2010;human clinical study using AFFITOPE® PD03A, confirming immunogenicity and safety profile in Parkinson's disease patients. http://www.affiris.com/news/affiris-announces-top-line-results-of-first-in-human-clinical-study-using-affitope/. Accessed on Feb 1, 2018.
50. Holmes BB, DeVos SL, Kfoury N, et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci U S A 2013;110(33):E3138-E3147.
51. Mao X, Ou MT, Karuppagounder SS, et al. Pathological alpha-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science 2016;353(6307):3374-1–3374-12. doi: 10.1126/science.aah3374
52. Neudorfer O, Giladi N, Elstein D, et al. Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM 1996;89(9):691-694.
53. Goker-Alpan O, Schiffmann R, LaMarca ME, Nussbaum RL, McInerney-Leo A, Sidransky E. Parkinsonism among Gaucher disease carriers. J Med Genet 2004;41(12):937-940.
54. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009;361(17):1651-1661.
55. Beavan MS, Schapira AH. Glucocerebrosidase mutations and the pathogenesis of Parkinson disease. Ann Med 2013;45(8):511-521.
56. Cilia R, Tunesi S, Marotta G, et al. Survival and dementia in GBA-associated Parkinson disease: the mutation matters. Ann Neurol 2016. doi: 10.1002/ana.24777.
57. Liu G, Boot B, Locascio JJ, et al. Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's. Ann Neurol 2016;80(5):674-685.
58. Davis MY, Johnson CO, Leverenz JB, et al. Association of GBA mutations and the E326K polymorphism with motor and cognitive progression in Parkinson disease. JAMA Neurol 2016;73(10):1217-1224.
59. Nalls MA, Duran R, Lopez G, et al. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol 2013;70(6):727-735.
60. Alcalay RN, Dinur T, Quinn T, et al. Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol 2014;71(6):752-757.
61. Mazzulli JR, Xu YH, Sun Y, et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011;146(1):37-52.
62. Sardi SP, Cheng SH, Shihabuddin LS. Gaucher-related synucleinopathies: The examination of sporadic neurodegeneration from a rare (disease) angle. Prog Neurobiol 2015;125C:47-62.
63. Aflaki E, Westbroek W, Sidransky E. The complicated relationship between Gaucher disease and parkinsonism: insights from a rare disease. Neuron 2017;93(4):737-746.
64. Schondorf DC, Aureli M, McAllister FE, et al. iPSC-derived neurons from GBA1-associated Parkinson's disease patients show autophagic defects and impaired calcium homeostasis. Nat Commun 2014;5:4028.
65. Taguchi YV, Liu J, Ruan J, et al. Glucosylsphingosine promotes alpha-synuclein pathology in mutant GBA-associated Parkinson's disease. J Neurosci 2017;37(40):9617-9631.
66. Sardi SP, Viel C, Clarke J, et al. Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models. Proc Natl Acad Sci U S A 2017;114(10):2699-2704.
67. Galvagnion C. The role of lipids interacting with alpha-synuclein in the pathogenesis of Parkinson's disease. J Parkinsons Dis 2017;7(3):433-450.
68. Zunke F, Moise AC, Belur NR, et al. Reversible conformational conversion of alpha-synuclein into toxic assemblies by glucosylceramide. Neuron 2017;S0896-6273(17)31135–2. doi: 10.1016/j.neuron.2017.12.012
69. Kim S, Yun SP, Lee S, et al. GBA1 deficiency negatively affects physiological alpha-synuclein tetramers and related multimers. Proc Natl Acad Sci U S A 2018;115(4):798–803. doi: 10.1073/pnas.1700465115
70. Gegg ME, Burke D, Heales SJ, et al. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol 2012;72(3):455-463.
71. Parnetti L, Chiasserini D, Persichetti E, et al. Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease. Mov Disord 2014;29(8):1019-1027.
72. Alcalay RN, Levy OA, Waters CC, et al. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. Brain 2015;138(Pt 9):2648-2658.
73. Sardi SP, Clarke J, Kinnecom C, et al. CNS expression of glucocerebrosidase corrects {alpha}-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy Proc Natl Acad Sci U S A 2011;108(29):12101-12106.
74. Sardi SP, Clarke J, Viel C, et al. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc Natl Acad Sci U S A 2013;110(9):3537-3542.
75. Rockenstein E, Clarke J, Viel C, et al. Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson's disease. Hum Mol Genet 2016;25(13):2645–2660. doi: 10.1093/hmg/ddw124.
76. Bartus RT, Weinberg MS, Samulski RJ. Parkinson's disease gene therapy: success by design meets failure by efficacy. Mol Ther 2014;22(3):487-497.
77. Migdalska-Richards A, Daly L, Bezard E, Schapira AH. Ambroxol effects in glucocerebrosidase and alpha-synuclein transgenic mice. Ann Neurol 2016;80(5):766-775.
78. Migdalska-Richards A, Ko WKD, Li Q, Bezard E, Schapira AHV. Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate. Synapse 2017;71(7). doi: 10.1002/syn.21967
79. Boyd RE, Lee G, Rybczynski P, et al. Pharmacological chaperones as therapeutics for lysosomal storage diseases. J Med Chem 2013;56(7):2705-2725.
80. Aflaki E, Borger DK, Moaven N, et al. A new glucocerebrosidase chaperone reduces alpha-synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with Gaucher disease and parkinsonism. J Neurosci 2016;36(28):7441-7452.
81. Mazzulli JR, Zunke F, Tsunemi T, et al. Activation of beta-glucocerebrosidase reduces pathological alpha-synuclein and restores lysosomal function in Parkinson's patient midbrain neurons. J Neurosci 2016;36(29):7693-7706.
82. Pastores GM, Hughes DA. Gaucher disease. In: Pagon RA, Adam MP, Ardinger HH, et al., eds. GeneReviews. Seattle, WA; University of Washington, Seattle 2015.
83. MJFF. First trial begins testing drug in people with GBA mutation. https://www.michaeljfox.org/foundation/news-detail.php?first-trial-begins-testing-drug-in-people-with-gba-mutation. Accessed on Feb 1, 2018.
84. Saunders-Pullman R, Mirelman A, Alcalay RN, et al. Progression in the LRRK2-associated Parkinson disease population. JAMA Neurol 2018.
85. Cookson MR. LRRK2 pathways leading to neurodegeneration. Curr Neurol Neurosci Rep 2015;15(7):42.
86. Cook DA, Kannarkat GT, Cintron AF, et al. LRRK2 levels in immune cells are increased in Parkinson's disease. NPJ Parkinsons Dis 2017;3:11.
87. West AB. Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease. Exp Neurol 2017;298(Pt B):236-245.
88. Fuji RN, Flagella M, Baca M, et al. Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Sci Trans Med 2015;7(273):273ra215.
89. Baptista MAS, Merchant KM, Bharghava S, et al. LRRK2 kinase inhibitors of different structural classes induce abnormal accumulation of lamellar bodies in type ii pneumocytes in non-human primates but are reversible and without pulmonary functional consequences. https://www.michaeljfox.org/foundation/publication-detail.html?id=594&category=9%202017. Accessed on Feb 1, 2018.
90. Zhao HT, John N, Delic V, et al. LRRK2 antisense oligonucleotides ameliorate alpha-synuclein inclusion formation in a Parkinson's disease mouse model. Mol Ther Nucleic Acid 2017;8:508-519.
91. Fan Y, Howden AJM, Sarhan AR, et al. Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils. Biochem J 2018;475(1):23-44.
92. Denali website. Denali therapeutics announces advancement and expansion of its LRRK2 inhibitor clinical program for Parkinson's disease. http://investors.denalitherapeutics.com/news-releases/news-release-details/denali-therapeutics-announces-advancement-and-expansion-its. Accessed on Feb 1, 2018.
93. Cedarbaum JM, Stephenson D, Rudick R, et al. Commonalities and challenges in the development of clinical trial measures in neurology. Neurotherapeutics 2015;12(1):151-169.
94. Weiner MW, Veitch DP, Aisen PS, et al. The Alzheimer's Disease Neuroimaging Initiative 3: continued innovation for clinical trial improvement. Alzheimers Dement 2017;13(5):561-571.
95. Weiner MW, Veitch DP, Aisen PS, et al. Recent publications from the Alzheimer's Disease Neuroimaging Initiative: reviewing progress toward improved AD clinical trials. Alzheimers Dement 2017;13(4):e1-e85.
96. Parkinson Progression Markers Initiative. The Parkinson Progression Marker Initiative (PPMI). http://www.ppmi-info.org/. Accessed on Feb 1, 2018.
97. Critical Path for Parkinson's. https://c-path.org/programs/cpp/. Accessed on Feb 1, 2018.
98. Conrado DJ, Nicholas T, Tsai K, et al. Dopamine transporter neuroimaging as an enrichment biomarker in early parkinson's disease clinical trials: a disease progression modeling analysis. Clin Trans Sci 2018;11(1):63-70.
99. EMA. Letter of support for molecular imaging of the dopamine transporter biomarker as an enrichment biomarker for clinical trials for early Parkinson's disease. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2016/10/WC500213914.pdf. Accessed on Feb 1, 2018.
100. Schrag A, Horsfall L, Walters K, Noyce A, Petersen I. Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. Lancet Neurol 2015;14(1):57-64.
101. Espay AJ, Bonato P, Nahab FB, et al. Technology in Parkinson's disease: challenges and opportunities. Mov Disord 2016;31(9):1272-1282.
102. Arneric SP, Cedarbaum JM, Khozin S, et al. Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem. Nat Rev Drug Discovery 2017;16(10):736.
103. Cedarbaum JM. Elephants, Parkinson's disease and “proof of concept” clinical trials. Mov Disord 2018; in press.